ArticleAnalytical chemistry2025
Fate of Stressed Oligoclonal Antibodies Tracked by Fluorescence Cross-Correlation Spectroscopy: IgG Aggregation Proceeds across the Species Barrier.
Article in Analytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody aggregation is a significant challenge in biopharmaceutical development, affecting drug efficacy and safety. This study applies fluorescence cross-correlation spectroscopy (FCCS) to analyze antibody aggregation, offering a novel approach to understanding this critical process. Our results demonstrated that aggregation can occur without species barriers, as evidenced by the correlated diffusion of different types of stressed antibodies. The absence of a species barrier is significant in elucidating aggregation mechanisms and ensuring the quality of therapeutic antibodies, particularly in oligoclonal formulations. Furthermore, we observed that the aggregation propensity of the antibody fragments (Fab and Fc) differed from that of full-length antibodies, emphasizing the need for a comprehensive analysis of both full-length antibodies and their fragments. Additionally, the self-aggregation propensity of fragments does not always align with their heteroaggregation propensity with preformed antibody aggregates. These findings emphasize the importance of advanced analytical methods to track heterogeneous aggregates accurately and provide insights into the aggregation dynamics of therapeutic antibodies under various conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.